Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem

14 settembre 2026 aggiornato da: Young-Kyun Lee, Seoul National University Bundang Hospital

Prospective Cohort Study of Primary Cementless Total Hip Arthroplasty Using Actis Stems

This study looks at how well a hip replacement using the collarless Actis stem works over five years.

Total hip replacement is a common operation for people whose hip joint has been damaged by arthritis, by loss of blood supply to the hip bone, or by a broken hip. During the operation, the damaged parts of the hip are replaced with artificial parts. The Actis stem is the part that is fitted into the thigh bone. It is designed to bond directly with the bone, without the use of bone cement.

The Actis stem is already used in many countries, and early results have been good. However, almost all of those results come from Western patients, and most studies used a version of the stem that has a small collar. Very little is known about how the collarless version performs in Asian patients, who tend to be younger at the time of surgery and more often have the operation because of loss of blood supply to the hip bone.

People aged 18 years or older who are already scheduled for a hip replacement at this hospital may take part. Everyone who takes part has the same operation, with the same set of artificial parts. No extra tests are done for research purposes.

After surgery, participants return to the clinic at 6 weeks, 3 months, and 12 months, and then once a year until 5 years have passed. These are the same visits that patients would have anyway. At each visit, the study team checks for any problems with the new hip, takes routine X-rays, and asks participants to fill in questionnaires about their hip pain, their daily activities, and their overall health.

The main question the study asks is how many participants have a problem with the new hip within five years, such as the hip coming out of place, an infection, a break in the bone around the implant, or the implant becoming loose.

Panoramica dello studio

Descrizione dettagliata

The collarless Actis stem is a cementless femoral component featuring a proximal DUOFIX hydroxyapatite coating and a triple-tapered geometry, intended to enhance proximal bone remodeling, promote favorable load distribution, and limit stress shielding. Favorable short-term outcomes have been reported by the manufacturer and in registry-based analyses, and a comparative series has shown results similar to those of the Corail stem. These data, however, derive almost entirely from Western populations, and the majority of published series have evaluated the collared version of the implant. No study has reported the outcomes of the collarless Actis stem in an East Asian population, in whom osteonecrosis of the femoral head is a more frequent indication for arthroplasty and the mean age at the time of surgery is lower than in Western cohorts.

All participants undergo primary cementless ceramic-on-ceramic total hip arthroplasty using the collarless Actis femoral stem and the Pinnacle acetabular cup, with a fourth-generation BIOLOX delta ceramic head and liner. Hybrid use of implants or ceramic bearings is precluded in order to avoid bias. All procedures are performed through a posterior approach with the patient in the lateral decubitus position. Component positioning follows a combined anteversion technique using anatomical landmarks, with a target cup anteversion of 37.3 degrees minus 0.7 times the stem anteversion.

At the routine preoperative medical clearance, participants are assessed for age, sex, body mass index, ambulatory function graded by the Koval classification, diagnosis, comorbidities, and operative risk according to the American Society of Anesthesiologists classification. Preoperative imaging comprises a three-dimensional computed tomography scan of the hip for planning, together with hip anteroposterior, hip cross-table lateral, pelvis lateral, and lumbosacral spine radiographs. Operative data include operative time, type of anesthesia, estimated blood loss, implant fixation, cup position, intraoperative complications, and length of hospital stay.

Postoperative mobilization begins on the first or second day after surgery, and participants ambulate with partial weight bearing using a walking aid for six weeks. Follow-up is scheduled at 6 weeks, 3 months, and 12 months after surgery and annually thereafter until 5 years, corresponding to the institution's routine postoperative schedule. No additional examinations are performed for research purposes beyond those obtained in routine care.

Serial hip anteroposterior and cross-table lateral radiographs are assessed for implant fixation, ceramic wear, osteolysis, implant loosening, and heterotopic ossification according to previously established criteria. Radiographic evaluation is performed by two independent observers who did not participate in the operations, with the six-week radiographs serving as the baseline for comparison. Patient-reported outcome measures are obtained preoperatively and at one year postoperatively and annually thereafter, and comprise the modified Harris Hip Score, the Hip Disability and Osteoarthritis Outcome Score, the EQ-5D, the University of California Los Angeles activity score, and the Forgotten Joint Score, the last of which is acquired postoperatively only.

The target enrollment of 210 hips was derived from an a priori power analysis. Assuming a complication rate of 6.5 percent, based on the investigators' previously reported 10- to 12-year outcomes of fourth-generation ceramic-on-ceramic total hip arthroplasty using the Pinnacle cup, 178 hips were required to detect a 2 percent difference with 80 percent power at a two-sided alpha of 0.05. Allowing for a 15 percent dropout rate, enrollment was set at 210 hips.

Data are recorded in an electronic case report form using a web-based REDCap platform and are monitored every six months for safety and data quality. Categorical data are summarized as counts and percentages and continuous data as means with standard deviations. Implant survivorship is analyzed using the Kaplan-Meier method with reoperation or revision as the endpoint.

Tipo di studio

Interventistico

Iscrizione (Stimato)

210

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Jung-Wee Park, MD
  • Numero di telefono: 82-31-787-7215
  • Email: jwepark@snubh.org

Luoghi di studio

    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
        • Reclutamento
        • Seoul National University Bundang Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Scheduled to undergo primary total hip arthroplasty for one of the following: osteoarthritis of the hip, developmental dysplasia of the hip, rheumatoid arthritis, non-rheumatoid inflammatory arthritis, post-traumatic arthritis, osteonecrosis of the femoral head, or displaced femoral neck fracture
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Age under 18 years
  • Total hip arthroplasty performed with a femoral stem other than the collarless Actis stem
  • Severe medical comorbidity precluding participation
  • Unwilling to participate in the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Actis
Participants undergo primary cementless total hip arthroplasty using the collarless Actis femoral stem with a Pinnacle acetabular cup and a fourth-generation ceramic-on-ceramic bearing, performed through a posterior approach with the patient in the lateral decubitus position.
Primary cementless total hip arthroplasty using the collarless Actis femoral stem and Pinnacle acetabular cup (DePuy Synthes, Warsaw, IN, USA) with a fourth-generation BIOLOX delta ceramic head and liner (CeramTec, Plochingen, Germany).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of orthopedic complications
Lasso di tempo: Up to 5 years after the index total hip arthroplasty
Number of participants with any orthopedic complication, defined as dislocation, periprosthetic joint infection, aseptic loosening, or periprosthetic fracture.
Up to 5 years after the index total hip arthroplasty

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Reoperation rate
Lasso di tempo: Up to 5 years after the index total hip arthroplasty
Number of participants undergoing any reoperation or revision of the index hip for any reason.
Up to 5 years after the index total hip arthroplasty
Implant survivorship
Lasso di tempo: Up to 5 years after the index total hip arthroplasty
Kaplan-Meier survivorship of the implant with reoperation or revision for any reason as the endpoint.
Up to 5 years after the index total hip arthroplasty
Modified Harris Hip Score
Lasso di tempo: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Modified Harris Hip Score, a measure of hip pain and function ranging from 0 to 100, with higher scores indicating better hip function.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Hip Disability and Osteoarthritis Outcome Score (HOOS)
Lasso di tempo: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
HOOS, a patient-reported measure scored from 0 to 100 in each subscale, with higher scores indicating fewer symptoms and better function.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
EQ-5D index score
Lasso di tempo: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
EQ-5D health-related quality of life index, with higher scores indicating better health status.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
University of California Los Angeles (UCLA) activity score
Lasso di tempo: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
UCLA activity score, ranging from 1 to 10, with higher scores indicating a higher level of physical activity.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Forgotten Joint Score (FJS)
Lasso di tempo: 1, 2, 3, 4, and 5 years after surgery
Forgotten Joint Score, ranging from 0 to 100, with higher scores indicating greater ability to forget the artificial joint in everyday life. Acquired postoperatively only.
1, 2, 3, 4, and 5 years after surgery
Radiographic findings
Lasso di tempo: 6 weeks to 5 years after surgery
Number of participants with radiographic evidence of implant loosening, osteolysis, ceramic wear, or heterotopic ossification on serial hip anteroposterior and cross-table lateral radiographs, assessed by two independent observers who did not participate in the operations. Six-week radiographs serve as the baseline for comparison.
6 weeks to 5 years after surgery
Incidence of medical complications
Lasso di tempo: Up to 5 years after the index total hip arthroplasty
Number of participants with deep vein thrombosis, pulmonary embolism, major adverse cardiac events, or death.
Up to 5 years after the index total hip arthroplasty

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Young-Kyun Lee, MD, Seoul National University Bundang Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 giugno 2025

Completamento primario (Stimato)

30 giugno 2031

Completamento dello studio (Stimato)

31 dicembre 2031

Date di iscrizione allo studio

Primo inviato

14 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 settembre 2026

Primo Inserito (Effettivo)

18 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data are the property of the sponsor institution and are subject to confidentiality obligations under the research support agreement. There is no plan to share individual participant data.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi